Vor Biopharma Q3 EPS $(0.49) Misses $(0.47) Estimate
Portfolio Pulse from Benzinga Newsdesk
Vor Biopharma reported Q3 losses of $0.49 per share, missing the analyst consensus estimate of $0.47 by 4.26%. However, this is a 22.22% improvement over the same period last year.
November 07, 2023 | 10:17 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Vor Biopharma's Q3 earnings per share (EPS) of $0.49 missed the consensus estimate of $0.47 by 4.26%, but improved by 22.22% compared to the same period last year.
Vor Biopharma's Q3 earnings missed the analyst consensus, which could negatively impact investor sentiment and potentially lead to a short-term drop in the stock price. However, the YoY improvement might mitigate this effect to some extent.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100